Organon | MSD

"We aspire to improve the lives of people globally by unleashing the promise of trusted brands across women’s health and other important therapeutic areas. We are committed to becoming the world’s leading women’s health company investing in innovations that support women’s well being"

Merck & Co., Inc., Kenilworth, NJ, USA (NYSE: MRK), known as MSD outside the United States and Canada, announced that Organon & Co. will be the name of a new company to be created through the intended spinoff of its women’s health, trusted legacy brands and biosimilars businesses. Fueled by its leading contraceptives and fertility businesses, Organon will invest in innovations that support the distinct health care needs of women today. Organon will also focus on its important biosimilars business, focusing on oncology and inflammatory diseases, while also maximizing the value of its trusted dermatology, pain, respiratory and cardiovascular portfolio in countries around the world where there is still great need for these treatments. Usage of the new company logo and brand is effective upon completion of the spinoff in the first half of 2021.

Areas of Focus

Share your CV and we may contact you about future opportunities.

Submit your CV
for Future Opportunities

This career site is intended for candidates interested in career opportunities at Organon & Co. Please note that if you are hired before the planned spin-off date, you will be employed by Merck & Co., Inc. Kenilworth, NJ, USA (or an associated legal entity) and then transferred to Organon & Co. Inc. If you are hired after the spin-off date you will be employed by Organon & Co. Inc. (or an associated legal entity). If you are an internal employee of Merck & Co., Inc. Kenilworth, NJ, USA, please speak to your Manager or HRBP to indicate your interest in Organon opportunities. We are an equal opportunity employer, proudly embracing diversity in all of its manifestations.